A gene at the heart of the disease
Most pancreatic cancers carry a mutation in a gene called KRAS. This gene helps cells grow and divide, and when it mutates, it can drive cancer. For years, scientists considered KRAS impossible to target with drugs. That view has changed recently. New medicines can block some KRAS mutations directly. Now researchers are testing a different approach: a vaccine that teaches the immune system to find and destroy cells carrying the mutated gene.
Early results
The experimental vaccine was tested in a small group of people at high risk of pancreatic cancer. The results showed that the vaccine produced a strong immune response. It appeared to be safe, with only mild side effects reported. The vaccine is designed to prevent cancer, not treat it. That makes it different from most cancer vaccines, which are given after a diagnosis. If it works, it could be given to people with a family history of the disease or known genetic risk.
What happens next
Researchers say the findings are preliminary. The trial was small, and it measured immune responses, not cancer outcomes. A larger study will be needed to show whether the vaccine actually prevents tumors. Pancreatic cancer is one of the deadliest cancers, with most patients diagnosed at a late stage. Survival rates have barely improved in decades. A working vaccine would change that picture. Scientists caution that the path from early promise to a licensed vaccine is long. But for a disease with so few options, even a small step forward draws attention.